Hospital-wide conversion achieves technology and sensor standardization,
creates process efficiencies and reduces costs
IRVINE, Calif., May 9 /PRNewswire-FirstCall/ -- Saint Barnabas Medical
Center and Masimo, the inventor of Pulse CO-Oximetry and
Measure-Through-Motion-and-Low-Perfusion Pulse Oximetry, have announced the
completion of Saint Barnabas Medical Center's hospital-wide implementation of
Masimo SET pulse oximetry. The New Jersey-based hospital performed an
extensive comparison and thorough evaluation spanning virtually every
department and cited superior performance, technology capabilities and future
clinical application as chief reasons for converting to Masimo SET.
"The decision to convert to Masimo SET pulse oximetry was multifaceted,
with numerous benefits that we didn't think were possible in one technology,"
said Shyan Sun, M.D., Director of Neonatology, Saint Barnabas Medical Center.
"With Masimo, we now have a standardized technology for oximetry that not only
enables sensor consistency and standardization across departments at reduced
costs, but also provides the system compatibility necessary to track oximetry
inventory and costs -- all in a technology platform that is uniquely
expandable to support our current and future oximetry needs."
Saint Barnabas Medical Center is the flagship of the Saint Barnabas Health
Care System, New Jersey's largest integrated health care delivery system, and
ranks among the top 5 percent of all hospitals in the country. The 601-bed
institution treats more patients annually and delivers more babies than any
other facility in New Jersey, including more than 40,000 inpatients admissions,
over 65,000 Emergency Department visits, and nearly 7,000 births each year.
Additionally, the Medical Center and its Ambulatory Care Center provide
treatment and services for more than 300,000 outpatient visits annually. The
Saint Barnabas Health Care System includes six acute care hospitals, a
behavioral health center, ambulatory care facilities, eight nursing and
rehabilitation centers, an assisted living facility, geriatric centers, a
state-wide behavioral health network, and comprehensive home care and hospice
programs.
Prior to their conversion, Saint Barnabas had a handful of various
oximetry monitors and technologies that each required different sensors from
different vendors -- eliminating the ability to purchase sensors in combined
volume. On top of this, these varying technologies were incompatible with the
hospital's inventory management program software and could not provide usable
data to track inventory movement and oximetry costs. Converting to Masimo SET
pulse oximetry helped Saint Barnabas Medical Center to overcome these
challenges, while reducing costs and creating process efficiencies that help
to improve the process of care.
In addition to Saint Barnabas's hospital-wide standardization to Masimo
SET pulse oximetry, the conversion also allows Saint Barnabas clinicians to
utilize Masimo Rainbow SET technology -- an upgradable noninvasive blood
constituent monitoring platform that is capable of measuring additional blood
constituents that previously could only be measured with invasive procedures.
Masimo Rainbow SET is the first and only method to continuously and
noninvasively measure total hemoglobin (SpHb(TM)) and oxygen content
(SpOC(TM)) (both pending regulatory clearances), carboxyhemoglobin (SpCO) and
methemoglobin (SpMet), in addition to oxyhemoglobin (SpO2), perfusion index
(PI), pleth variability index (PVI) and pulse rate. Developed as a scalable
and upgradable technology platform, Masimo Rainbow SET enables clinicians and
hospitals to do more with their Masimo devices by building and expanding the
noninvasive measurements, capabilities and features within the platform. This
allows hospitals to make an investment in patient safety today that won't
become obsolete tomorrow.
By making the conversion to Masimo, Saint Barnabas joins many of the top
hospitals in the United States -- including four of the top five -- as listed
on the US News & World Report Honor Roll, which have all adopted Masimo SET as
their primary pulse oximetry platform. Clinically proven in more than 100
independent and objective studies, Masimo SET provides the most trustworthy
SpO2 readings, even under the most difficult clinical conditions, including
patient motion and low peripheral perfusion. These studies demonstrate that
Masimo SET delivers improvements in outcomes, safety and efficiency.
Joe E. Kiani, CEO of Masimo, stated, "Saint Barnabas Medical Center's
conversion to Masimo SET pulse oximetry ensures they have the best of the
present and are set for the future with the upgradable Masimo Rainbow SET
technology platform. They represent a growing industry trend toward pulse
oximetry technologies that have value and relevance into the future. Masimo
Rainbow SET is the first pulse oximetry technology platform to pioneer this
capability and the only one that can provide the innovation to drive this
proposition for hospitals worldwide. We value Saint Barnabas for their
commitment to patient care, quality and this vision."
About Masimo
Masimo (Nasdaq: MASI) develops innovative monitoring technologies that
significantly improve patient care-helping solve "unsolvable" problems. In
1995, the company debuted Measure-Through-Motion-and-Low-Perfusion pulse
oximetry, known as Masimo SET, which virtually eliminated false alarms and
increased pulse oximetry's ability to detect life-threatening events. More
than 100 independent and objective studies demonstrate Masimo SET provides the
most reliable SpO2 and pulse rate measurements even under the most challenging
clinical conditions, including patient motion and low peripheral perfusion. In
2005, Masimo introduced Masimo Rainbow SET, a breakthrough noninvasive blood
constituent monitoring platform that can measure many blood constituents that
previously required invasive procedures. Rainbow SET continuously and
noninvasively measures total hemoglobin (SpHb(TM)) and oxygen content
(SpOC(TM)) (both pending regulatory clearances), carboxyhemoglobin (SpCO(R)),
methemoglobin (SpMet(R)), and PVI(TM), in addition to oxyhemoglobin (SpO2),
pulse rate (PR), and perfusion index (PI), allowing early detection and
treatment of potentially life-threatening conditions. Founded in 1989, Masimo
has the mission of "Improving Patient Outcomes and Reducing Cost of Care by
Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at
http://www.masimo.com.
Forward Looking Statements
This press release may include forward-looking statements. These
forward-looking statements are based on current expectations about future
events affecting us and are subject to uncertainties and factors, all of which
are difficult to predict and many of which are beyond our control, including:
risks related to our assumption that Masimo SET and Masimo Rainbow SET will
deliver a sufficient level of clinical improvement over alternative pulse
oximetry and noninvasive patient monitoring systems to allow for further
adoption of the technology at other hospitals, risks related to our assumption
that this agreement with Saint Barnabas will serve to substantially increase
revenues, and risks related to our assumption that Masimo's new noninvasive
measurements -- total hemoglobin (SpHb(TM)) and oxygen content (SpOC(TM)) --
will deliver a sufficient level of clinical improvement over alternative
hemoglobin testing capabilities to allow for rapid adoption of the technology
and risks related to our assumptions regarding the timing or commercial
availability of SpHb and SpOC, and will be timely cleared, if ever, by
appropriate regulatory bodies, as well as other factors discussed in the "Risk
Factors" section of our annual report on Form 10-Q for the quarter ended March
29, 2008, filed with the Securities and Exchange Commission on May 1, 2008.
Although we believe that the expectations reflected in our forward-looking
statements are reasonable, we do not know whether our expectations will prove
correct. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. We do not
undertake any obligation to update, amend or clarify these forward-looking
statements or the risk factors contained in our annual report on Form 10-Q for
the quarter ended March 29, 2008, whether as a result of new information,
future events or otherwise, except as may be required under the federal
securities laws.
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing
Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications,
Rainbow, SpCO, SpMet, PVI, Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
SOURCE Masimo Corporation
CONTACT: Dana Banks of Masimo Corporation, +1-949-297-7348
Web site: http://www.masimo.com